Impact of Levetiracetam and Carbamazepine on Patients with Refractory Epilepsy
Objective To observe the impact of levetiracetam and carbamazepine on cognitive function,epilepsy attack indicators,and serum indicators in patients with refractory epilepsy.Methods A total of 88 patients with refractory epilepsy treated in Nanyang Central Hospital from September 2022 to September 2023 were selected as the research subjects.They were randomly divided into the reference group(n=44)and the research group(n=44)based on the random number table method.The reference group was treated with carbamazepine,and the research group was treated with levetiracetam.The cognitive function,epilepsy attack indicators,serum neurotrophic factor indicators,and adverse reactions of the two groups were compared and analyzed.Results After treatment,the scores of the Wechsler Adult Intelligence Scale(WAIS-RC)for verbal IQ,performance IQ,and total IQ in the research group were all higher than those in the reference group,with statistically significant differences(P＜0.05).After treatment,the frequency and score of epilepsy attacks in the research group were lower than those in the reference group,with statistically significant differences(P＜0.05).After treatment,the levels of neuron-specific enolase(NSE),central nervous system-specific protein β(S100β),and myelin basic protein(MBP)in the research group were all lower than those in the reference group,with statistically significant differences(P＜0.05).The incidence of adverse reactions in the research group was lower than that in the reference group,with a statistically significant difference(P＜0.05).Conclusion Levetiracetam can effectively improve the cognitive function of patients with refractory epilepsy,reduce the frequency and duration of epilepsy attacks,and improve the expression of related serum neurotrophic factors.
国家科技期刊平台
NSTL
万方数据
